Evans WE - Search Results

1

Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine.

Crom WR, Relling MV, Christensen ML, Rivera GK, Evans WE. Crom WR, et al. Among authors: evans we. Clin Pharmacol Ther. 1991 Aug;50(2):132-40. doi: 10.1038/clpt.1991.117. Clin Pharmacol Ther. 1991. PMID: 1868674

2

Disposition of antineoplastic agents in the very young child.

McLeod HL, Relling MV, Crom WR, Silverstein K, Groom S, Rodman JH, Rivera GK, Crist WM, Evans WE. McLeod HL, et al. Among authors: evans we. Br J Cancer Suppl. 1992 Aug;18:S23-9. Br J Cancer Suppl. 1992. PMID: 1503923 Free PMC article. Review.

3

Variability in teniposide plasma protein binding is correlated with serum albumin concentrations.

Petros WP, Rodman JH, Relling MV, Christensen M, Pui CH, Rivera GK, Evans WE. Petros WP, et al. Among authors: evans we. Pharmacotherapy. 1992;12(4):273-7. Pharmacotherapy. 1992. PMID: 1518726

4

Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects.

Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Relling MV, et al. Among authors: evans we. Clin Pharmacol Ther. 1991 Sep;50(3):308-13. doi: 10.1038/clpt.1991.141. Clin Pharmacol Ther. 1991. PMID: 1680593

5

Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.

Evans WE, Rodman JH, Relling MV, Petros WP, Stewart CF, Pui CH, Rivera GK. Evans WE, et al. J Pharmacol Exp Ther. 1992 Jan;260(1):71-7. J Pharmacol Exp Ther. 1992. PMID: 1731053

6

Increased teniposide clearance with concomitant anticonvulsant therapy.

Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH. Baker DK, et al. Among authors: evans we. J Clin Oncol. 1992 Feb;10(2):311-5. doi: 10.1200/JCO.1992.10.2.311. J Clin Oncol. 1992. PMID: 1732431

7

Anticancer therapy as a pediatric pharmacodynamic paradigm.

Evans WE, Relling MV, Rodman JH, Crom WR. Evans WE, et al. Dev Pharmacol Ther. 1989;13(2-4):85-95. doi: 10.1159/000457589. Dev Pharmacol Ther. 1989. PMID: 2693007 Review.

8

Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children.

Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J Jr, Crom WR. Evans WE, et al. Clin Pharmacol Ther. 1989 May;45(5):568-73. doi: 10.1038/clpt.1989.74. Clin Pharmacol Ther. 1989. PMID: 2721111

9

Hepatic drug clearance in children: studies with indocyanine green as a model substrate.

Evans WE, Relling MV, de Graaf S, Rodman JH, Pieper JA, Christensen ML, Crom WR. Evans WE, et al. J Pharm Sci. 1989 Jun;78(6):452-6. doi: 10.1002/jps.2600780605. J Pharm Sci. 1989. PMID: 2760818

10

Lorazepam pharmacodynamics and pharmacokinetics in children.

Relling MV, Mulhern RK, Dodge RK, Johnson D, Pieper JA, Rivera GK, Evans WE. Relling MV, et al. Among authors: evans we. J Pediatr. 1989 Apr;114(4 Pt 1):641-6. doi: 10.1016/s0022-3476(89)80713-9. J Pediatr. 1989. PMID: 2926577

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

629 results

Search Page